Lilly to Supply Bamlanivimab to US Government Pending EUA Decision
Bamlanivimab is a potent neutralizing IgG1 monoclonal antibody directed against the spike protein of severe acute respiratory syndrome coronavirus 2.
Vaccinations
COVID-19 Vaccine Allocation: Ethical Concerns, Practical Challenges
In the event of a likely scarcity of COVID-19 vaccines, a framework must be developed to inform who should get priority.
HPV Vaccination Associated With Reduced Risk of Invasive Cervical Cancer
Study authors assessed the relationship between quadrivalent HPV vaccination and risk of invasive cervical cancer and age of vaccination.
Trial of Antibody Drug for COVID-19 Stopped for Lack of Effectiveness
An antibody drug for hospitalized COVID-19 patients has been halted because the treatment does not help them recover from their infection.
Novel Pneumococcal Conjugate Vaccine Immunogenic in Phase 3 Trials
Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.
FDA Approves Veklury as First Treatment for COVID-19
The FDA approved Veklury (remdesivir; Gilead Sciences) for the treatment of COVID-19 in patients aged ≥12 years (weighing ≥40kg) requiring hospitalization.
Survey Reveals Factors Contributing to COVID-19 Vaccine Acceptance
To estimate the association between attribute level and probability of choosing and receiving a vaccine, the study authors calculated the average marginal component effects sizes as well as marginal means.
Immunogenicity of 2-Dose Ebola Vaccine Regimens
Regardless of interval or dose level, both heterologous and homologous Ad26, MVA Ebola vaccine regimens were observed to be well tolerated in healthy adults.
First Treatment for Ebola Virus Gets FDA Approval
Atoltivimab, maftivimab, and odesivimab-ebgn is a combination of Zaire ebolavirus
glycoprotein directed recombinant human IgG1 human monoclonal antibodies.
Futility Concerns Halt C difficile Vaccine Trial
The efficacy, immunogenicity, and safety of a Clostridioides difficile toxoid vaccine candidate was assessed.
-
Loading...
-
Loading...
Next post in Nosocomial Infections
